| Literature DB >> 31791375 |
Chiara Robba1, Giulia Bonatti2,3, Denise Battaglini2,3, Patricia R M Rocco4, Paolo Pelosi2,3.
Abstract
Most patients with ischaemic stroke are managed on the ward or in specialty stroke units, but a significant number requires higher-acuity care and, consequently, admission to the intensive care unit. Mechanical ventilation is frequently performed in these patients due to swallowing dysfunction and airway or respiratory system compromise. Experimental studies have focused on stroke-induced immunosuppression and brain-lung crosstalk, leading to increased pulmonary damage and inflammation, as well as reduced alveolar macrophage phagocytic capability, which may increase the risk of infection. Pulmonary complications, such as respiratory failure, pneumonia, pleural effusions, acute respiratory distress syndrome, lung oedema, and pulmonary embolism from venous thromboembolism, are common and found to be among the major causes of death in this group of patients. Furthermore, over the past two decades, tracheostomy use has increased among stroke patients, who can have unique indications for this procedure-depending on the location and type of stroke-when compared to the general population. However, the optimal mechanical ventilator strategy remains unclear in this population. Although a high tidal volume (VT) strategy has been used for many years, the latest evidence suggests that a protective ventilatory strategy (VT = 6-8 mL/kg predicted body weight, positive end-expiratory pressure and rescue recruitment manoeuvres) may also have a role in brain-damaged patients, including those with stroke. The aim of this narrative review is to explore the pathophysiology of brain-lung interactions after acute ischaemic stroke and the management of mechanical ventilation in these patients.Entities:
Keywords: Brain injury; Brain-lung crosstalk; Intensive care unit; Mechanical ventilation; Stroke
Mesh:
Year: 2019 PMID: 31791375 PMCID: PMC6889568 DOI: 10.1186/s13054-019-2662-8
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1Brain-systemic crosstalk. After stroke, stimulation of the vagus nerve through nicotinic acetylcholine receptor α7 (nAChRα7) induces microglial activation, causing reduced alveolar macrophage phagocytic capability and reducing circulating levels of interleukin IL-6 and tumour necrosis factor TNF-α, thus leading to an anti-inflammatory reflex and lung injury. On the other hand, systemic inflammation consequent to stroke leads to an increased release of inflammatory mediators such as IL-6 and TNF-α, resulting in lung inflammation and alveolar-capillary injury. Finally, a sympathetic response with increased expression of inflammatory mediators and hypothalamic-pituitary-adrenal axis activation induces elevated glucocorticoid secretion, which might be associated with secondary infections and poor outcome
Fig. 2The role of the vagal pathways in the development of lung injury. The healthy brain can control excess cytokine production via an inflammatory reflex of the vagus nerve (by activation of the afferent vagus through the celiac ganglion). Stimulation of the vagus nerve through nicotinic acetylcholine receptor α7 (nAChRα7) regulates microglial activation in the brain, protects neuronal cells from oxidative stress, and improves functional recovery, contributing to immunosuppression. Expression of nAChRα7 on alveolar macrophages and epithelial cells induces a reduction of inflammation in the lungs, and, by suppressing the production of pro-inflammatory cytokines (IL-6, TNF-α) through lipopolysaccharides (LPS) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFK-B), impairs host defence during inflammatory conditions. Altogether, vagal stimulation during stroke blunts macrophage capabilities, with increased risk of infection and lung injury, while paradoxically inducing a higher anti-inflammatory response and thus decreasing the risk of lung injury. The balance between these two pathways accounts for the occurrence, or not, of lung injury. Ach, acetylcholine; NA, noradrenaline
Studies evaluating the use of oxygen therapy in acute ischaemic stroke patients
| Authors | Design | Aim | Participants | Total ( | O2 therapy | Conclusions |
|---|---|---|---|---|---|---|
| Rønning et al. 1999 [ | Quasi-randomised trial | To test the hypothesis that breathing 100% O2 for the first 24 h after an AS would not reduce mortality, impairment, or disability | AS | 555 (66/555 ICH) | O2 therapy (100% atm, 3 L/min for 24 h [ | Supplemental O2 should not routinely be given to non-hypoxic stroke victims with minor or moderate strokes. |
| Ali et al. 2005 [ | Prospective study | To assess the effects of different doses and routes of O2 administration on SatO2 in patients with stroke | AS | 21 (15 AIS; 6 ICH) | Steps: -Room air for 30 min; − 2-3 L/min of O2 (nasal cannula) -FiO2 0.24 (VM) -FiO2 0.3535% (VM) -Room air | There was a dose-response relationship between the amount of O2 given and the resultant changes in SatO2. |
| Singhal et al. 2005 [ | Randomised trial | To investigate the effects of high-flow oxygen (HFO) in AIS | AIS | 16 | HFO (humidified O2 at 45 L/min via facemask for 8 h [ | HFO is associated with a transient improvement of clinical deficits and MRI abnormalities in select patients with AIS. |
| Chiu et al. 2006 [ | Prospective study | To investigate the feasibility of eubaric hyperoxia therapy by VM in a group of patients who experienced a severe AIS | AIS | 46 | O2 therapy (FiO2 0.4via VM [ | By using VM therapy with a FiO2 of 0.4, there might be less mortality and comorbidities in treated patients who experienced a severe AIS. |
| Singhal et al. 2007 [ | RCT | To investigate the metabolic effects of normobaric oxygen (NBO) on AIS brain tissues using MRSI and diffusion-perfusion MRI | AIS | 6 | NBO (45 L/min O2 via face mask for 8 h [ | NBO improves aerobic metabolism and preserves neuronal integrity in AIS brain. |
| Padma et al. 2010 [ | Randomised trial | To study the role of NBO in AIS in Indian patients | AIS | 40 | NBO (10 L/min O2 for 12 h [ | NBO did not improve the clinical scores of stroke outcome in Indian patients with AIS. |
| Roffe et al. 2011 [ | RCT | To report the effects of routine use of O2 supplementation for 72 h on SatO2 and neurological outcomes at 1 week after an AS | AS (clinical diagnosis) | 289 (257 AIS, 24 ICH, 8 undetermined) | O2 therapy (O2 via nasal cannula for 72 h [ | Routine O2 supplementation started within 24 h of hospital admission with AS led to a small, but statistically significant, improvement in neurological recovery at 1 week. The difference in NIHSS improvement may be due to baseline imbalance in stroke severity between the two groups. |
| Ali et al. 2013 [ | RCT | To report the effects of routine O2 supplementation for 72 h on SatO2 and neurological outcomes at 6 months after AS | AS (clinical diagnosis) | 289 (257 AIS, 24 ICH, 8 undetermined) | O2 therapy (O2 via nasal cannula for 72 h [ | None of the key outcomes differed at 6 months between the groups. Although not statistically significant and generally of small magnitude, the effects were predominantly in favour of the O2 group. |
| Jeon et al., 2014 [ | Prospective, observational cohort study | To determine the association between exposure to hyperoxia and the risk of DCI after SAH | SAH | 252 | Hyperoxia (the highest quartile of an area under the curve of PaO2, until the development of DCI [PaO2 ≥ 173 mmHg]) | Exposure to excess O2 after SAH may represent a modifiable factor for morbidity and mortality in this population. |
| Rincon et al. 2014 [ | Retrospective multicentre cohort study | To test the hypothesis that hyperoxia was associated with higher in-hospital mortality in ventilated AS patients admitted to the ICU | AS | 2894 (554 AIS, 936 SAH, 1404 ICH) | O2 therapy to obtain PaO2 ≥ 300 mmHg | Hyperoxia was an independent predictor of in-hospital death. |
| Mazdeh et al. 2015 [ | RCT | To evaluate the effects of normobaric hyperoxia on clinical outcomes of patients with severe AS | AS | 52 | O2 therapy (VM for 12 h) versus controls (no O2) | NBO therapy in the first 12 h of AS could improve long-time outcome of the patients with either ischaemic or haemorrhagic stroke. |
| Roffe et al., 2017 [ | Multicentre single-blind RCT | To assess whether routine prophylactic use of low-dose O2 therapy was more effective than control O2 administration at reducing death and disability at 90 days, and if so, whether O2 given at night only, when hypoxia is most frequent, and O2 administration is least likely to interfere with rehabilitation, was more effective than continuous supplementation | AS (clinical diagnosis) | 8003 (6555 AIS, 588 ICH, 294 AS without CT diagnosis, 168 TIA, 292 non-stroke diagnoses, 106 missing data) | Continuous O2 (2–3 L/min via nasal cannula for 72 h [ | Among non-hypoxic patients with AS, the prophylactic use of low-dose O2 supplementation did not reduce death or disability at 3 months. |
| Ding et al. 2018 [ | Meta-analysis | To analyse the current data of NBO on brain protection as used in the clinical settings | AS | 6366 | NBO group (… [ | The existing trends toward benefits revealed in this meta-analysis help us appreciate the promising value of NBO, although current evidence of NBO on improving clinical outcomes of stroke is insufficient. |
| Roffe et al. 2018 [ | Multicentre, prospective, randomised, open, blinded-end point trial | (1) To assess whether or not routine low-dose of O2 supplementation in patients with AS improves outcome compared with no O2 and (2) to assess whether or not O2 given at night only, when SatO2 is most likely to be low, is more effective than continuous supplementation | AS (clinical diagnosis) | 8003 (6555 AIS, 588 ICH, 168 TIA, 292 non-stroke diagnoses, 106 missing data) | Continuous O2 (2–3 L/min via nasal cannula for 72 h [ | Routine use of low-dose O2 supplementation in stroke patients who are not severely hypoxic is safe but does not improve outcome after AS. |
AIS acute ischaemic stroke, AS acute stroke (including haemorrhagic), atm atmospheres, DCI delayed cerebral ischaemia, FiO fraction of inspired oxygen, HFO high-flow oxygen, ICH intracerebral haemorrhage, MRI magnetic resonance imaging, MRSI multivoxel magnetic resonance spectroscopic imaging, NBO normobaric oxygen, PaO partial pressure of oxygen, RCT randomised controlled trial, SatO oxygen saturation, SDH subdural haemorrhage, TIA transient ischaemic attack, VM venturi mask
Respiratory management of patients with stroke according to 2018 AHA/ASA guidelines [23]
| Intubation and ventilation are recommended in patients with decreased consciousness, bulbar dysfunction with inability to protect the airway, or intracranial hypertension (level I). | |
| Aim for normoxia and normocapnia (NA). | |
| Continuous monitoring of oxygenation is strongly recommended in patients with AIS in ICU. Supplemental oxygen should be administered if SpO2 > 94% (level I). | |
| Supplemental oxygen is not recommended in non-hypoxic patients (level III). | |
| Hyperbaric oxygen is not recommended, except in case of air embolism (level III). |
AIS acute ischemic stroke, ICU intensive care unit, SpO2 oxygen saturation
Causes of intubation in stroke patients
| GCS < 9 | |
| Airway compromise | |
| Apnoea | |
| Hypoxaemia despite supplemental oxygen | |
| Impaired swallowing and gag reflexes | |
| Inability to clear secretions | |
| Seizures or drugs suppressing respiratory drive | |
| Need for intracranial pressure management | |
| Anticipated neurological or cardiopulmonary decline requiring transport or immediate treatment |
GCS Glasgow Coma Scale
Fig. 3Recommended mechanical ventilation strategies for patients with acute ischaemic stroke. Abbreviations: PEEP, positive end-expiratory pressure; O2, oxygen; CO2, carbon dioxide